ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

January 24, 2008 10:58 ET

ALDA Pharmaceuticals Invited to Ottawa HIV Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 24, 2008) - Representatives of ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") have been invited to attend the 4th Canadian Microbicides Symposium that will take place on January 28, 2008, in Ottawa, Ontario. The event is being organized by the Canadian AIDS Society and is being attended by a select group of approximately 40 invitees from government departments, research organizations, the private sector and community organizations. The goal of the symposium is to implement the Canadian Microbicide Action Plan (CMAP), which is a commitment from Canada to contribute to microbicides both domestically and internationally, with an emphasis on the urgent need for improved products. The AIDS epidemic is in its third decade and it is now very evident that the scale of the AIDS crisis outstrips even the worst case scenarios of a decade ago. Since 1981, 25 million people have died of AIDS worldwide. The CMAP is an important initiative because, globally, it is estimated that 33.2 million people are now infected with HIV/AIDS with 6,800 new cases being reported every day.

ALDA's representatives have also been invited to meet with members of the Senate of Canada on Parliament Hill in Ottawa on January 29th, 2008.

Participation in this symposium and the subsequent private meetings will provide exposure of ALDA's T36® Microbicide Gel to government and non-government organizations (NGO's), public and private organizations and companies that are striving to prevent the spread of HIV and AIDS.

The CMAP was completed in 2006 and includes recommendations on policy and regulatory issues, cross-departmental and cross-sector mechanisms for collaboration, and steps to strengthen commitments to accelerate the development and delivery of microbicides. CMAP is the only plan of its kind in the world. ALDA is privileged to have the opportunity to participate in this multi-sectoral symposium for the purpose of articulating domestic and global contributions from Canada through the CMAP.

About T36® Microbicide Gel

T36® Microbicide Gel is a personal lubricant that is designed to prevent the spread of HIV and other Sexually Transmitted Infections ("STI's"). It contains infection-control ingredients in relatively low concentrations that act synergistically to disrupt the physical structure of microbes rather than interfering with their metabolic pathways. The competitive advantage is its ability to kill STI-causing organisms while preventing microbial resistance, side effects or toxicity.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information